SNA02-48

SNA02-48 is a **recombinant fully human monoclonal antibody** that specifically targets **tetanus toxin**. Developed to provide passive immunization for **post-exposure prophylaxis and treatment of tetanus**, SNA02-48 aims to address the limitations of traditional serum-derived products such as human and equine tetanus immunoglobulins. By utilizing a fully human antibody library platform, this drug reduces the risk of allergic reactions and serum sickness associated with heterologous proteins, offering a safer option especially for individuals sensitive to animal sera. SNA02-48 is indicated for prevention of tetanus in non-neonatal patient populations and is positioned as a next-generation alternative for tetanus post-exposure management[1][5][6].